Clinical Trial

Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial

Study acronym: ID-COMET
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This protocol is comprised of three unblinded, randomized, single-center studies to evaluate the impact of immediate versus three-month delayed comprehensive ablative treatment on survival in newly diagnosed metastatic patients with lung (Trial 1), colorectal (Trial 2), and prostate (Trial 3) cancers
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2024-08-18; most recent amendment 2026-02-02.
Status change: Not Yet Recruiting → Recruiting 2024-09-06
Trial Details
NCT Number NCT06563388
Lead Sponsor Roswell Park Cancer Institute
Conditions Oligometastasis, Lung Cancer, Colo-rectal Cancer, Prostate Cancer
Enrollment 800 participants
Start Date 2024-09-18
Primary Completion 2032-09-18 (estimated)
Study Completion 2032-09-18 (estimated)
Updated on ClinicalTrials.gov 2026-02-04